G. Dawson

发表

Imitation in Rats: Initial Responding and Transfer Evidence

C. Heyes, G. Dawson, T. Nokes, 1992 .

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls

G. Dawson, J. Deakin, C. Harmer, 2017, Molecular Psychiatry.

Relating constructs of attention and working memory to social withdrawal in Alzheimer’s disease and schizophrenia: issues regarding paradigm selection

G. Dawson, M. Havenith, J. Glennon, 2019, Neuroscience & Biobehavioral Reviews.

Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze

G. Dawson, A. Simmons, Steven C. R. Williams, 2011, Journal of psychopharmacology.

The GABA-A &bgr;3 subunit mediates anaesthesia induced by etomidate

G. Dawson, R. Fradley, G. O'Meara, 2004, Neuroreport.

Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 Subtypes

G. Dawson, H. Burns, J. Atack, 2010, Journal of Pharmacology and Experimental Therapeutics.

Contribution of GABAA receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys

G. Dawson, J. Atack, D. M. Platt, 2011, Psychopharmacology.

Title Page Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial-Agonist

G. Dawson, H. Burns, J. Atack, 2009 .

Blockade of alcohol's amnestic activity in humans by an α5 subtype benzodiazepine receptor inverse agonist

David J. Nutt, G. Dawson, D. Nutt, 2007, Neuropharmacology.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA Receptor α5 Subtype-Selective Inverse Agonist

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009, Journal of Pharmacology and Experimental Therapeutics.

The plasma–occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, α5IA, is similar in rats and primates

G. Dawson, J. Atack, R. Hargreaves, 2009, British journal of pharmacology.

In Vitro and in Vivo Properties of 3-tert-Butyl-7-(5-methylisoxazol-

A. D. Rodrigues, K. Gingrich, G. Dawson, 2009 .

RESEARCH PAPER The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, a5IA, is similar in rats and primates

G. Dawson, H. Burns, J. Atack, 2009 .

Role of GABAA alpha5-containing receptors in ethanol reward: the effects of targeted gene deletion, and a selective inverse agonist.

G. Dawson, D. Stephens, J. Atack, 2005, European journal of pharmacology.

Selective, Orally Active γ-Aminobutyric AcidA α5 Receptor Inverse Agonists as Cognition Enhancers

Desmond O'Connor, G. Dawson, J. Atack, 2004 .

The proconvulsant effects of the GABAA α5 subtype-selective compound RY-080 may not be α5-mediated

G. Dawson, R. Mckernan, J. Atack, 2006 .

Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer’s disease patients

G. Dawson, J. Ayuso-Mateos, M. Kas, 2022, PloS one.

A comparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory

G. Dawson, S. Iversen, S. Channell, 2005, Psychopharmacology.

Loss of the Major GABAA Receptor Subtype in the Brain Is Not Lethal in Mice

G. Dawson, R. Mckernan, P. Whiting, 2001, The Journal of Neuroscience.

Feasibility, acceptability and costs of nurse-led Alpha-Stim cranial electrostimulation to treat anxiety and depression in university students

G. Dawson, L. Price, S. Royal, 2022, BMC Primary Care.

Novel aspects of accumulation dynamics and Aβ composition in transgenic models of AD

G. Dawson, R. Kalaria, S. Qian, 2004, Neurobiology of Aging.

Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders

G. Dawson, J. Ayuso-Mateos, B. Sommer, 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety

G. Dawson, D. Nutt, C. Dourish, 2011, Journal of psychopharmacology.

Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): Role of GABAA receptor subtypes

G. Dawson, J. Atack, S. C. Licata, 2010, Neuropharmacology.

Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands

G. Dawson, P. Whiting, J. Atack, 2007, Journal of psychopharmacology.

P.172 Preliminary fMRI results exploring brain activity in a spatial navigation task in schizophrenia, Alzheimer's Disease, and healthy controls

G. Dawson, B. Sommer, M. Kas, 2019, European Neuropsychopharmacology.

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

G. Dawson, S. Tye, R. Mckernan, 2006, Journal of Pharmacology and Experimental Therapeutics.

APP Knockout and APP Over-Expression in Transgenic Mice

G. Dawson, S. Boyce, Gurparkash Singh, 1997 .

Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.

G. Dawson, R. Mckernan, A. Pike, 2004, Journal of medicinal chemistry.

Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys

G. Dawson, W. Sieghart, J. Atack, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Reinforcing Effects Of Compounds Lacking Intrinsic Efficacy At α1 Subunit-Containing GABAA Receptor Subtypes in Midazolam- But Not Cocaine-Experienced Rhesus Monkeys

G. Dawson, J. Atack, E. Sawyer, 2013, Neuropsychopharmacology.

GABAA α1 subunit knock-out mice do not show a hyperlocomotor response following amphetamine or cocaine treatment

G. Dawson, P. Whiting, T. Rosahl, 2003, Neuropharmacology.

RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708

G. Dawson, R. Mckernan, J. Atack, 2006, Drug Metabolism and Disposition.

Evaluation of [methyl-3H]L655,708 and [ethyl-3H]RY80 as putative PET ligands for central GABAA receptors containing α5 subunit

G. Dawson, S. Luthra, S. Hume, 1999 .

Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptors

G. Dawson, R. Mckernan, J. Atack, 2005 .

3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues: High-Affinity γ-Aminobutyric Acid-A Benzodiazepine Receptor Ligands with α2, α3, and α5-Subtype Binding Selectivity over α1

G. Dawson, P. Leeson, R. Mckernan, 2004 .

3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.

G. Dawson, P. Leeson, R. Mckernan, 2004, Journal of medicinal chemistry.

6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists.

G. Dawson, J. Atack, H. Broughton, 2002, Journal of medicinal chemistry.

The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines

G. Dawson, L. McDonald, Joanna L Stanley, 2005, Journal of psychopharmacology.

Interactions between LY354740, a Group II metabotropic agonist and the GABAA-benzodiazepine receptor complex in the rat elevated plus-maze

G. Dawson, E. Seward, P. Ferris, 2001, Journal of psychopharmacology.

Use of the elevated plus maze in the search for novel anxiolytic agents.

G. Dawson, M. Tricklebank, 1995, Trends in pharmacological sciences.

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy

G. Dawson, J. Deakin, L. Wilkinson, 2011, Psychopharmacology.

Effects of drugs that potentiate GABA on extinction of positively-reinforced operant behaviour

G. Dawson, C. McCabe, J. Leslie, 2004, Neuroscience & Biobehavioral Reviews.

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs

G. Dawson, S. Iversen, S. Tye, 1995, Psychopharmacology.

Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate

G. Dawson, D. Downey, J. Deakin, 2016, European Neuropsychopharmacology.

Heptylphysostigmine — Novel Acetylcholinesterase Inhibitor: Biochemical and Behavioral Pharmacology

G. Dawson, S. Iversen, L. Iversen, 1991 .

The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory

G. Dawson, S. Iversen, Susan D. Iversen, 1993, Behavioural Brain Research.

The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents

G. Dawson, S. Iversen, G. Bentley, 1991, Pharmacology Biochemistry and Behavior.

A quantitative trait locus influencing anxiety in the laboratory rat.

G. Dawson, J. Gray, R. Mott, 2002, Genome research.

β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity

G. Dawson, S. Boyce, Hui Zheng, 1995, Cell.

Genetic Mapping of Variation in Spatial Learning in the Mouse

G. Dawson, J. Flint, Joanna L Stanley, 2003, The Journal of Neuroscience.

Lack of consistent behavioural effects of Maudsley reactive and non-reactive rats in a number of animal tests of anxiety and activity

G. Dawson, J. Gray, J. Flint, 2001, Psychopharmacology.

Sedation and Anesthesia Mediated by Distinct GABAA Receptor Isoforms

G. Dawson, T. Iwatsubo, I. Nishimoto, 2003, The Journal of Neuroscience.

Alpha2-containing GABAA receptors are involved in mediating stimulant effects of cocaine

G. Dawson, D. Stephens, T. Rosahl, 2008, Pharmacology Biochemistry and Behavior.

Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates.

G. Dawson, J. Atack, J. Rowlett, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Evidence for a Significant Role of α3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines

G. Dawson, R. Dias, S. Tye, 2005, The Journal of Neuroscience.

Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition.

G. Dawson, 2016, Current topics in behavioral neurosciences.

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.

G. Dawson, R. Mckernan, A. Pike, 2005, Journal of medicinal chemistry.

Pharmacological mechanisms and animal models of cognition.

C. Heyes, G. Dawson, S. Iversen, 1992, Behavioural pharmacology.

Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies

G. Dawson, J. Deakin, U. Ettinger, 2016, Translational psychiatry.

A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study

G. Dawson, L. Wilkinson, J. Deakin, 2012, European Neuropsychopharmacology.

Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation

G. Dawson, P. Coloma, M. Potenza, 2023, Neuroscience & Biobehavioral Reviews.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

G. Dawson, R. Mohs, C. Harmer, 2016, Neuropsychopharmacology.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

G. Dawson, R. Mohs, C. Harmer, 2016, Neuropsychopharmacology.

An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.

G. Dawson, J. Atack, D. O'connor, 2004, Journal of medicinal chemistry.

Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: a modelling study

G. Dawson, C. Harmer, G. Goodwin, 2019, Evidence-Based Mental Health.

The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial

G. Dawson, C. Harmer, G. Goodwin, 2017, Trials.

Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients.

G. Dawson, J. Ayuso-Mateos, B. Sommer, 2020, Journal of psychiatric research.

Predicting treatment response to antidepressant medication using early changes in emotional processing

G. Dawson, C. Harmer, G. Goodwin, 2019, European Neuropsychopharmacology.

The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial

G. Dawson, C. Harmer, G. Goodwin, 2021, Neuropsychopharmacology.

Development of Subtype Selective GABAA Modulators

G. Dawson, J. Atack, N. Collinson, 2005, CNS Spectrums.

Lack of effect of flumazenil and CGS 8216 on the anxiolytic-like properties of loreclezole.

G. Dawson, M. Tricklebank, P. Bayley, 1994, European journal of pharmacology.

Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)

G. Dawson, D. Nutt, C. Dourish, 2011, Journal of psychopharmacology.

Learned fear, emotional reactivity and fear of heights: a factor analytic map from a large F2 intercross of Roman rat strains

G. Dawson, J. Gray, J. Flint, 2002, Brain Research Bulletin.

Optimizing Behavioral Paradigms to Facilitate Development of New Treatments for Anhedonia and Reward Processing Deficits in Schizophrenia and Major Depressive Disorder: Study Protocol

G. Dawson, T. van Amelsvoort, A. Hayen, 2020, Frontiers in Psychiatry.

Agomelatine facilitates positive versus negative affective processing in healthy volunteer models

G. Dawson, P. Cowen, C. Harmer, 2011, Journal of psychopharmacology.

On the elevated plus-maze the anxiolytic-like effects of the 5-HT1A agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT1A partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635

G. Dawson, N. Collinson, 1997, Psychopharmacology.

Validation of the P1vital® Faces Set for Use as Stimuli in Tests of Facial Emotion Recognition

G. Dawson, Jason M. Thomas, S. Higgs, 2022, Frontiers in Psychiatry.

The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone

G. Dawson, R. Mckernan, J. Atack, 2006, Neuropharmacology.

Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity

G. Dawson, S. Iversen, M. Tricklebank, 1995, Psychopharmacology.

The effects of ketamine and risperidone on eye movement control in healthy volunteers

G. Dawson, L. Wilkinson, S. Williams, 2013, Translational Psychiatry.

Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat

G. Dawson, R. Dias, D. O'connor, 2005, Journal of psychopharmacology.

Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide.

G. Dawson, J. Leslie, D. Reynolds, 2005, Journal of the experimental analysis of behavior.

Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved?

G. Dawson, R. Mckernan, D. Reynolds, 2001, Trends in pharmacological sciences.

Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour

G. Dawson, J. Atack, C. McCabe, 2004, Neuropharmacology.

One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure

G. Dawson, S. Iversen, M. Tricklebank, 2005, Psychopharmacology.

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors

G. Dawson, R. Mckernan, J. Atack, 2006, Neuropharmacology.

Identification of a Novel, Selective GABAA α5 Receptor Inverse Agonist Which Enhances Cognition

G. Dawson, J. Atack, H. Broughton, 2003 .

3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels

G. Dawson, R. Mckernan, A. Pike, 2002 .

Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

G. Dawson, R. Mckernan, J. Atack, 2005, British journal of pharmacology.

Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.

G. Dawson, K. Craig, C. Dourish, 2011, Biochemical pharmacology.

A STRATEGY TO HOME-IN ON POLYGENES INFLUENCING SUSCEPTIBILITY TO ANXIETY

G. Dawson, J. Gray, J. Flint, 1999 .

Experimental medicine in psychiatry

G. Dawson, G. Goodwin, 2005, Journal of psychopharmacology.

Predictive validity in drug discovery: what it is, why it matters and how to improve it

G. Dawson, J. Scannell, J. Hickman, 2022, Nature Reviews Drug Discovery.

P.2.f.013 A precision medicine approach to antidepressant treatment in depression

G. Dawson, C. Harmer, M. Browning, 2015, European Neuropsychopharmacology.

From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

Stephen R. Morairty, Robert T. Smith, G. Dawson, 2021, Cell.

Conducting CNS trials during a public health emergency – Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper

G. Dawson, J. Verster, D. Bugarski-Kirola, 2023, Neuroscience Applied.

Neuroscience and Biobehavioral Reviews Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer ’ s disease

G. Dawson, R. Kahn, M. Kas, 2022 .

Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.

G. Dawson, C. Dourish, 2014, Biomarkers in medicine.

The screening of novel compounds on behavioral task performance and fMRI brain activations in a surrogate patient population ( high schizo types ) is a promising approach for the development of the next generation of therapies to treat schizophrenia

G. Dawson, C. Dourish, 2013 .

Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic

G. Dawson, D. Nutt, A. Rich, 2013, Journal of psychopharmacology.

G. Dawson, G. Dawson, S. Boyce, 1999, Neuroscience.

Special issue on CNS experimental medicine

G. Dawson, G. Goodwin, C. Dourish, 2011, Journal of psychopharmacology.

Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment

G. Dawson, C. Harmer, M. Browning, 2021, Journal of psychopharmacology.

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

G. Dawson, R. Elliott, C. Harmer, 2023, Schizophrenia.

Predicting treatment response to antidepressant medication using early changes in emotional processing

G. Dawson, C. Harmer, G. Goodwin, 2019, European Neuropsychopharmacology.

Dawson and tricklebank reply

G. Dawson, M. Tricklebank, 1995 .

Reducing Abuse Liability of GABA A /Benzodiazepine Ligands via Selective Partial Agonist Efficacy at (cid:1) 1 and (cid:1) 2/3 Subtypes

G. Dawson, J. Atack, H. Burns, 2009 .

P.048 Results of the predict randomised controlled trial: clinical effects of using the predict test to guide antidepressant treatment in depression

G. Dawson, G. Goodwin, V. Pérez, 2019, European Neuropsychopharmacology.